



Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejancer.com



Corrigendum

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]



Toni K. Choueiri ^{a,*}, Colin Hessel ^b, Susan Halabi ^c, Ben Sanford ^d,
M. Dror Michaelson ^e, Olwen Hahn ^f, Meghara Walsh ^a,
Thomas Olencki ^g, Joel Picus ^h, Eric J. Small ⁱ, Shaker Dakhil ^j,
Darren R. Feldman ^k, Milan Mangeshkar ^b, Christian Scheffold ^b,
Daniel George ^{l,1}, Michael J. Morris ^{k,1}

^a Dana-Farber/Partners CancerCare, Boston, MA, USA

^b Exelixis Inc., South San Francisco, CA, USA

^c Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA

^d Alliance Statistics and Data Center, Duke University, Durham, NC, USA

^e Massachusetts General Hospital Cancer Center, Boston, MA, USA

^f Alliance Protocol Operations Office, Chicago, IL, USA

^g The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

^h Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA

ⁱ UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

^j University of Kansas – Wichita, Wichita, KS, USA

^k Memorial Sloan Kettering Cancer Center, New York, NY, USA

^l Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA

The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined):

As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group).

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ejca.2018.02.012>.

* Corresponding author: Dana Farber Cancer Institute, 450 Brookline Avenue, DANA 1230, Boston, MA 02215, USA. Fax: +1 617 632 2165.

E-mail address: toni_choueiri@dfci.harvard.edu (T.K. Choueiri).

¹ Authors contributed equally to this work.

<https://doi.org/10.1016/j.ejca.2018.09.022>

0959-8049/© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).